BRIEF-Intra-Cellular Therapies Reports Positive Phase 3 Results For Caplyta In Schizophrenia Relapse Prevention

Reuters11-05 20:04

Nov 5 (Reuters) - Intra-Cellular Therapies Inc :

* INTRA-CELLULAR THERAPIES ANNOUNCES POSITIVE TOPLINE RESULTS IN PHASE 3 TRIAL EVALUATING CAPLYTA FOR THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA

* INTRA-CELLULAR THERAPIES INC - PRIMARY ENDPOINT SHOWS LONGER TIME TO RELAPSE WITH LUMATEPERONE

* INTRA-CELLULAR THERAPIES INC - 18 RELAPSES IN LUMATEPERONE GROUP VERSUS 44 IN PLACEBO GROUP

* INTRA-CELLULAR THERAPIES INC - LUMATEPERONE MEETS KEY SECONDARY ENDPOINT IN STUDY

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481777275?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-05 20:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481777275","market":"us","top_or_hot":-1,"title":"BRIEF-Intra-Cellular Therapies Reports Positive Phase 3 Results For Caplyta In Schizophrenia Relapse Prevention","media":"Reuters","content":"<html><body><p>Nov 5 (Reuters) - Intra-Cellular Therapies Inc   :</p><p>   * INTRA-CELLULAR THERAPIES ANNOUNCES POSITIVE TOPLINE RESULTS IN PHASE 3 TRIAL EVALUATING CAPLYTA FOR THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA</p><p>   * INTRA-CELLULAR THERAPIES INC - PRIMARY ENDPOINT SHOWS LONGER TIME TO RELAPSE WITH LUMATEPERONE</p><p>   * INTRA-CELLULAR THERAPIES INC - 18 RELAPSES IN LUMATEPERONE GROUP VERSUS 44 IN PLACEBO GROUP</p><p>   * INTRA-CELLULAR THERAPIES INC - LUMATEPERONE MEETS KEY SECONDARY ENDPOINT IN STUDY</p><p>Source text:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Intra-Cellular Therapies Reports Positive Phase 3 Results For Caplyta In Schizophrenia Relapse Prevention</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Intra-Cellular Therapies Reports Positive Phase 3 Results For Caplyta In Schizophrenia Relapse Prevention\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-05 20:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 5 (Reuters) - Intra-Cellular Therapies Inc   :   * INTRA-CELLULAR THERAPIES ANNOUNCES POSITIVE TOPLINE RESULTS IN PHASE 3 TRIAL EVALUATING CAPLYTA FOR THE PREVENTION OF RELAPSE IN PATIENTS WITH ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2481777275","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481777275","pubTimestamp":1730808247,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Nov 5  - Intra-Cellular Therapies Inc   :   * INTRA-CELLULAR THERAPIES ANNOUNCES POSITIVE TOPLINE RESULTS IN PHASE 3 TRIAL EVALUATING CAPLYTA FOR THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA   * INTRA-CELLULAR THERAPIES INC - PRIMARY ENDPOINT SHOWS LONGER TIME TO RELAPSE WITH LUMATEPERONE   * INTRA-CELLULAR THERAPIES INC - 18 RELAPSES IN LUMATEPERONE GROUP VERSUS 44 IN PLACEBO GROUP   * INTRA-CELLULAR THERAPIES INC - LUMATEPERONE MEETS KEY SECONDARY ENDPOINT IN STUDYSource text:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","ITCI":"Intra-Cellular Therapies Inc.","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD"},"translate_title":"Brief-IntraCellular Therapies报告Caplyta预防精神分裂症复发的3期积极结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ITCI":1},"content_text":"Nov 5 (Reuters) - Intra-Cellular Therapies Inc   :   * INTRA-CELLULAR THERAPIES ANNOUNCES POSITIVE TOPLINE RESULTS IN PHASE 3 TRIAL EVALUATING CAPLYTA FOR THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA   * INTRA-CELLULAR THERAPIES INC - PRIMARY ENDPOINT SHOWS LONGER TIME TO RELAPSE WITH LUMATEPERONE   * INTRA-CELLULAR THERAPIES INC - 18 RELAPSES IN LUMATEPERONE GROUP VERSUS 44 IN PLACEBO GROUP   * INTRA-CELLULAR THERAPIES INC - LUMATEPERONE MEETS KEY SECONDARY ENDPOINT IN STUDYSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481777275"}